Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: A southwest oncology group trial (S0204)

Journal of Clinical Oncology

Volumn 27, Issue 21, 2009, Pages 3510-3517

  Hussein, Mohamad A ^a   Bolejack, Vanessa ^a   Zonder, Jeffrey A ^a   Durie, Brian G M ^a   Jakubowiak, Andrzej J ^a   Crowley, John J ^a   Barlogie, Bart ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BLOOD TOXICITY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; QUALITY OF LIFE; TIME;

DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; QUALITY OF LIFE; THALIDOMIDE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 70249097029     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.9240     Document Type: Article

References (20)

1. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-936, 2006
2. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
3. Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789-793, 1997
4. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
5. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006
6. Barlogie B, Pineda-Roman M, van Rhee F, et al: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115-3121, 2008
7. Rajkumar SV, Blood E, Vesole D, et al: A randomized phase III clinical trial of thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006
8. Greipp P, San Miguel J, Durie B, et al: International Staging System for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
9. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
10. Harousseau J-L, Attal M, Moreau P, et al: The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM): Combined results of the IFM 99 trials. Blood 108, 2006 (abstr 3077)
11. Gooley TA, Leisering W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Mantel N: Evaluation of survival data and two new rank order statistics arising in it consideration. Cancer Chemotherapy Reports 50:163-170, 1966
14. Cox DR: Regression tables and life tables. J Royal Statistical Soc B 34:187-202, 1972
15. Attal M, Harousseau JL: Role of autologous stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 4:747-759, 2007
16. Attal M, Harousseau J-L, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
17. Abdelkefi A, Ladeb S, Torjman L, et al: Single autologous transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 111: 1805-1810, 2008
18. Mehta J: One or two autografts for myeloma. Blood 111:3899-3900, 2008
19. Pineda-Roman M, Zangari M, Haessler J, et al: Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol 140:625-634, 2008
20. Barlogie B, Anaissie E, Shaughnessy J, et al: Ninety percent sustained complete response (CR) rate projected 4 years after onset of CR in GEP-defined low-risk multiple myeloma (MM) treated with total therapy 3 (TT3). Am Soc Hematol in press (abstr)